Biotechnology firm Denali Therapeutics said that it has appointed Tim Van Hauwermeiren to its board of directors. He is co‑founder and CEO of argenx.
The company announced that its Chief Medical Officer and Head of Development since 2015, Carole Ho, M.D., will depart to join Eli Lilly and Company as Executive Vice President and President of Lilly Neuroscience.
Denali stated that Peter Chin, M.D., neurologist and senior vice president of the Enzyme TransportVehicle™ franchise and late‑stage clinical development, will assume the role of Acting Chief Medical Officer and Head of Development.
Denali indicated that Dr. Ho will transition responsibilities to Dr. Chin through late November 2025.
According to the company, the leadership changes align with its transition from clinical‑stage to commercial‑stage operations and readiness for potential product approval and launch. The company said the new board appointment brings scientific insight and commercial leadership as it advances its TransportVehicle platform and prepares for the first product launch.
Denali described itself as a biotechnology firm developing a portfolio of candidates engineered to cross the blood‑brain barrier for neurodegenerative and lysosomal storage diseases.
The company noted that all forward‑looking statements made in relation to these changes are subject to risks and uncertainties, including regulatory approvals, commercialization challenges and dependence on its platform technology.
